Study Background and Disease Burden
Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disorder characterized primarily by synovial inflammation and joint destruction, leading to significant disability and decreased quality of life. Despite advances in disease-modifying antirheumatic drugs (DMARDs), including methotrexate (MTX), a substantial proportion of patients exhibit inadequate clinical response or intolerance to MTX, necessitating alternative therapies. Janus kinase (JAK) inhibitors have emerged as an effective treatment option, targeting intracellular cytokine signaling pathways to control disease activity. However, JAK inhibitor therapy is frequently accompanied by elevations in total cholesterol, LDL cholesterol, triglycerides, and creatinine kinase—metabolic alterations that may attenuate the overall therapeutic benefit by increasing cardiovascular risk and other adverse events.
Given this limitation, the dual inhibition strategy combining JAK and Rho-associated protein kinase (ROCK) pathways has been proposed. ROCK inhibitors have demonstrated cardioprotective effects in preclinical models through mechanisms such as reducing vascular inflammation, improving endothelial function, and preventing cardiac remodeling. Leveraging this approach, CPL409116 (hereafter CPL’116) is a novel oral agent designed to simultaneously inhibit JAK and ROCK activity, aiming to provide effective RA disease control with reduced cardiometabolic side effects. This phase 2 trial investigated the dose-dependent efficacy, safety, and pharmacokinetics of CPL’116 in patients with moderate-to-severe RA who had an inadequate response to stable MTX therapy.
